NRX Pharmaceuticals
Manufacturing · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1201 N Orange St Ste 600, Wilmington, De...Phone Number
(484) 254-6134Website
www.nrxpharma.comRevenue
<$5 MillionStock Symbol
NRXPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for central nervous system disorders, including life-threatening forms of depression and post-traumatic stress disorder. It uses a scientific platform targeting the brains NMDA receptor to advance drug candidates such as preservative-free ketamine formulations and oral therapies designed to address unmet needs in severe mental health conditions. The company also supports healthcare delivery through its interventional psychiatry clinic network.Explore more
NRX Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NRX Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NRX Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once NRX Pharmaceuticals has new funding data
Click to see if NRX Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when NRX Pharmaceuticals launches new products
NRX Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if NRX Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if NRX Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on NRX Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined NRX Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to NRX Pharmaceuticals
Compare insights from companies similar to NRX Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NRX Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NRX Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NRX Pharmaceuticals.
NRX Pharmaceuticals financials insights
Gather financial insights about NRX Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$25M
Debt
$11M
2024
Share Placement
$5M
Debt
$16M
2025
Other Financing Round
$8.9M
NRX Pharmaceuticals Tech Stack
A closer look at the technologies used by NRX Pharmaceuticals
See more technologies
Most Recent Scoops
New Hire
Executive Move
Glenn Tyson has recently joined the organization as Chief Commercial Officer.
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Project
NRX Pharmaceuticals has noted that the upcoming trial involves only a day or a couple of days of D-cycloserine treatment rather than six weeks, reducing the risk that patients might not be compliant with the study drug to near zero.
Pharmaceuticals, Clinical Operations, Patient Experience
Project
Pharmaceuticals, Artificial Intelligence, Healthcare Technology
NRX Pharmaceuticals News & Media
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its subsidiary, HOPE Therapeutics, Inc. ("HOPE"), has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System. HOPE has installed Zeta TMS Navigation Systems at its clinics in West Palm Beach and Sarasota, Florida, with Zeta-navigated patient treatments now undZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
SARASOTA, Fla, and BOSTON, June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today announced the first patient treatment with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota. HOPE has...NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
WILMINGTON, Del., June 22, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the approval by FDA of an Intermediate Population Expanded Access Protocol for the use of NRX-101, a fixed dose combination of D-cycloserine (DCS) and lurasidone for the augmentation of accelerated Transcranial Magnetic Stimulation (TMS). Expanded Access Protocols are part ofNRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), featuring a year-to-date gain of 52.77% and upside potential of 987.00%, secures a spot on our list of hot biotech stocks under $5 to buy. A clinical-stage biopharmaceutical company focused on bringing suicide-prevention drugs to market, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), just closed a capital raise that provides it with a fresh […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NRX Pharmaceuticals
Sign Up For FreeTo access detailed company insights
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for central nervous system disorders, including life-threatening forms of depression and post-traumatic stress disorder. It uses a scientific platform targeting the brains NMDA receptor to advance drug candidates such as pr... Read More
